Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SM04755 · 1 trial · 4 indications
| Arm | Type | Description |
|---|---|---|
| SM04755 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| SM04755 | DRUG | Escalating Doses |
Inclusion Criteria: * Subjects with advanced colorectal, gastric, hepatic or pancreatic cancer * Subjects must have recovered from all toxicity associated with previous chemotherapy, targeted therapy, or radiotherapy * Subjects must meet certain laboratory criteria * Expected survival \> 3months * ...
Top 20 of 77 competitors
SM04755 is an investigational small molecule being studied for the treatment of advanced colorectal cancer, as well as gastric, hepatic, and pancreatic cancers. It is in Phase 1 clinical development and has not been approved by the FDA.
SM04755 is being developed by cbdMD, Inc., a company traded on the NYSE American under the ticker YCBD. The drug is currently in Phase 1 clinical development for oncology indications.
SM04755 is in Phase 1 clinical development. It has completed one Phase 1 trial and is not yet approved by the FDA. The drug remains investigational and is being evaluated for safety and pharmacokinetics in patients with advanced cancers.
SM04755 has been studied in one completed Phase 1 trial, NCT02191761, titled 'Safety and Pharmacokinetics of SM04755 in Subjects With Advanced Colorectal, Gastric, Hepatic, or Pancreatic Cancer.' The trial enrolled 13 participants in the United States and was not randomized or blinded.
SM04755 is a small molecule being developed for oncology. Its specific molecular target has not been disclosed in available information, so its mechanism of action is not described here.